Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Airway Epithelium Gene Expression: AEGIS II

Study:

Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS II

Rationale:

n/a

Purpose:

The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cancer, and this difference in gene expression may be a biomarker for lung cancer.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Lung Cancer Device: Biomarker (not used as an intervention) N/A

Verified by Allegro Diagnostics, Corp. November, 2012

Sponsored by: Allegro Diagnostics, Corp.
Information provided by: Allegro Diagnostics, Corp.
ClinicalTrials.gov identifier: NCT00746759

Study Type: Interventional

Study Design: Observational Model: Cohort, Time Perspective: Prospective

Cleveland Clinic
Cleveland, Ohio
United States

Duncan Whitney, PhD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.